Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 183 clinical trials
None
Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System

Background Researchers are testing version of a system known as a magnetic resonance imagining (MRI) scanner that uses strong magnetic fields, radio waves and the like to create images of the organs in the body. It uses lower energy levels than other MRI scanners. This may help scan people with …

cardiovascular disease
vasodilator
chest pain
ejection fraction
Accepts healthy volunteers
  • 25 views
  • 02 Nov, 2021
  • 1 location
None
Study to Improve OS in 18 to 60 Year-old Patients Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following …

blast cells
consolidation chemotherapies
cyclosporine
methotrexate
vosaroxin
  • 42 views
  • 25 Jan, 2021
  • 57 locations
None
An Open-Label Multicenter Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, when administered alone and in combination with low-dose cytarabine (LDAC) or Decitabine for the treatment of adults

cytarabine
refractory acute myeloid leukemia (aml)
decitabine
cancer
  • 2 views
  • 10 Sep, 2021
  • 44 locations
None
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing

blast cells
methotrexate
daunorubicin
mitoxantrone
gemtuzumab
  • 5 views
  • 27 Oct, 2021
  • 95 locations
None
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma Ependymoma and ATRT

, and alternating cycles of daily low-dose oral etoposide and cyclophosphamide), augmented with alternating courses of intrathecal etoposide and cytarabine. The aim of the study is to extend therapy

medulloblastoma
combinations
ependymoma
karnofsky performance status
bevacizumab
  • 40 views
  • 17 Sep, 2021
  • 27 locations
None
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

. Drugs used in chemotherapy, such as vincristine, dexamethasone, prednisone, prednisolone, pegaspargase, methotrexate, cytarabine, mercaptopurine, doxorubicin, cyclophosphamide, and thioguanine, work in

mercaptopurine oral suspension
cyclophosphamide
monoclonal antibody therapy
methotrexate
vincristine
  • 84 views
  • 14 Nov, 2021
  • 119 locations
None
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

tolerated dose (MTD) for gilteritinib in sequential combination with fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG). The purpose of the phase 2 portion (dose expansion) is to

blast cells
remission
serum bilirubin level
colony stimulating factor
refractory acute myeloid leukemia (aml)
  • 1 views
  • 30 Nov, 2021
  • 19 locations
None
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations

course of DA or intermediate dose Cytarabine (IDAC) as a third course. Patients who are MRD negative by flow cytometry after course one of CPX-351 will receive up to 2 further course of CPX. Patients

high risk myelodysplastic syndrome
daunorubicin
leukemia
myelodysplastic syndrome with excess blasts-2
flow cytometry
  • 381 views
  • 23 Jan, 2021
  • 83 locations
None
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL Mixed Phenotype Acute Leukemia and B-LLy

. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine

cyclophosphamide
monoclonal antibody therapy
cancer chemotherapy
methotrexate
vincristine
  • 44 views
  • 12 Sep, 2021
  • 114 locations
None
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by …

blast cells
bone marrow procedure
myeloid leukemia
daunorubicin
mitoxantrone
  • 153 views
  • 25 Oct, 2021
  • 142 locations